Table II.
Genotype | Smoke (pack-years) | Male
|
Female
|
||||
---|---|---|---|---|---|---|---|
Cases/controls, n | OR (95% CI)a | Pinteraction | Cases/controls, n | OR (95% CI)a | Pinteraction | ||
CYP1A2*1F | 0.805 | <0.001 | |||||
AC/CC | Never | 60/62 | 1.0 | 55/79 | 1.0 | ||
AA | Never | 78/86 | 0.99 (0.61–1.60) | 60/62 | 1.35 (0.80–2.25) | ||
AC/CC | ≤20 | 50/43 | 1.11 (0.64–1.94) | 31/27 | 1.51 (0.78–2.91) | ||
AA | ≤20 | 42/47 | 0.94 (0.53–1.64) | 35/24 | 2.31 (1.21–4.42) | ||
AC/CC | >20 | 74/44 | 1.75 (1.03–2.97) | 38/22 | 2.24 (1.15–4.38) | ||
AA | >20 | 81/72 | 1.06 (0.64–1.73) | 45/16 | 4.36 (2.15–8.84) | ||
Ptrend | 0.430 | <0.001 | |||||
SULT1A1 | 0.023 | <0.001 | |||||
GG | Never | 59/52 | 1.0 | 43/53 | 1.0 | ||
GA/AA | Never | 79/96 | 0.76 (0.47–1.25) | 72/89 | 0.97 (0.57–1.65) | ||
GG | ≤20 | 27/33 | 0.73 (0.38–1.41) | 19/21 | 1.00 (0.46–2.19) | ||
GA/AA | ≤20 | 60/53 | 0.94 (0.54–1.62) | 43/30 | 1.91 (1.00–3.62) | ||
GG | >20 | 49/48 | 0.84 (0.48–1.47) | 38/19 | 2.45 (1.18–5.08) | ||
GA/AA | >20 | 97/69 | 1.21 (0.72–2.01) | 44/18 | 2.96 (1.45–6.06) | ||
Ptrend | 0.330 | <0.001 | |||||
NAT1 | 0.408 | 0.012 | |||||
Non*10 | Never | 88/101 | 1.0 | 70/96 | 1.0 | ||
*10 | Never | 50/47 | 1.22 (0.74–2.02) | 45/46 | 1.34 (0.78–2.29) | ||
Non*10 | ≤20 | 62/56 | 1.18 (0.73–1.89) | 45/38 | 1.64 (0.93–2.87) | ||
*10 | ≤20 | 25/30 | 0.92 (0.49–1.73) | 17/13 | 1.98 (0.89–4.44) | ||
Non*10 | >20 | 97/82 | 1.24 (0.81–1.90) | 55/27 | 2.71 (1.50–4.89) | ||
*10 | >20 | 49/35 | 1.55 (0.91–2.66) | 27/10 | 4.01 (1.73–9.29) | ||
Ptrend | 0.300 | <0.001 | |||||
NAT2 | 0.021 | 0.002 | |||||
R/I | Never | 62/53 | 1.0 | 56/65 | 1.0 | ||
Slow | Never | 76/95 | 0.65 (0.40–1.06) | 59/77 | 0.81 (0.48–1.36) | ||
R/I | ≤20 | 39/38 | 0.80 (0.44–1.45) | 23/21 | 1.47 (0.72–3.03) | ||
Slow | ≤20 | 48/48 | 0.77 (0.44–1.37) | 39/30 | 1.34 (0.71–2.53) | ||
R/I | >20 | 58/51 | 0.87 (0.51–1.51) | 39/16 | 2.71 (1.30–5.65) | ||
Slow | >20 | 88/66 | 1.03 (0.62–1.71) | 43/21 | 2.27 (1.16–4.46) | ||
Ptrend | 0.622 | 0.001 |
R/I = rapid/intermediate.
OR was adjusted for age, family history of cancer, history of diabetes and alcohol consumption.